Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : LEI-101
Catalog No.: PC-20747Not For Human Use, Lab Use Only.
LEI-101 (LEI 101) is a potent, selective, orally available and peripherally restricted cannabinoid CB2 receptor agonist with binding pKi of 7.5 (hCB2R).
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
LEI-101 (LEI 101) is a potent, selective, orally available and peripherally restricted cannabinoid CB2 receptor agonist with binding pKi of 7.5 (hCB2R).
LEI-101 displays 100‐fold selectivity for CB2 receptors over CB1 receptors in binding assays, does not interact with other proteins of the endocannabinoid system: human FAAH (hFAAH), MAGL, NAPE‐PLD and DAGL.
LEI‐101 behaves as a CB2 receptor partial agonist in the β‐arrestin recruitment and GTPγS assays with pEC50 of 8.0 and 7.0, respectively.
LEI‐101 (60 mg/kg, p.o.) does not induce cannabimimetic effects in vivo.
LEI‐101 (3.0 or 10 mg/kg, p.o. and i.p.) attenuates biomarkers and histological damage of cisplatin‐induced nephropathy in C57Bl6/J mice, prevents cisplatin‐induced increases in serum creatinine and BUN levels.
LEI‐101 attenuates cisplatin‐induced renal 3‐nitrotyrosine (3‐NT) formation, attenuates cisplatin (Cis)‐induced renal HNE adducts formation in wild type, but not in CB2R‐/‐ mice.
| M.Wt | 472.54 | |
| Formula | C23H25FN4O4S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Mukhopadhyay P, et al. Br J Pharmacol. 2016 Feb;173(3):446-58.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
